A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia
Müller-Tidow, Carsten, Bug, Gesine, Lübbert, Michael, Krämer, Alwin, Krauter, Jürgen, Valent, Peter, Nachbaur, David, Berdel, Wolfgang E., Ottmann, Oliver G., Fritsch, Holger, Munzert, Gerd, Garin-CheLanguage:
english
Journal:
British Journal of Haematology
DOI:
10.1111/bjh.12518
Date:
August, 2013
File:
PDF, 435 KB
english, 2013